Royalty Report: Drugs, Drug Discovery, Therapeutic – Collection: 249718

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 20

Primary Industries

  • Drugs
  • Drug Discovery
  • Therapeutic
  • Disease
  • Diagnostic
  • Proteins
  • Data Management
  • Medical Info
  • HIV / AIDs
  • Assay
  • Content

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 249718

License Grant
Licensor grants an exclusive, worldwide, right and license, within the Territory and within the Field, to use the Licensor Know-How and Patent Rights and undivided interest in any Program Intellectual Property and Program Patent Rights that are jointly owned by Licensor and Licensee, as embodied in or related to Designated Compounds, to identify, research, develop, make, have made and use such Designated Compound to develop Licensed Products and to develop, make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products; provided, that the exclusivity of such license shall be subject in the case of Generic Patent Rights to the retained rights.
License Property
The licensed property is:
(a) the NeoMorph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Preliminary Compounds,
(e) the Primary Active Compounds,
(f) the Selected Compounds, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof made by Licensor, and
(g) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Programs.

The NeoMorph Screening Library consists of approximately 10,000,000 diverse small organic compounds.

Field of Use
Field means the diagnosis, prevention and/or treatment of any and all diseases in humans.

Licensor synthesize small molecule compounds as mixtures in a format that enables ALIS to efficiently screen proteins. Our proprietary NeoMorph library, consisting of over 10 million diverse small molecules, is stored as approximately 5,000 mixtures, each containing approximately 2,000 mass-encoded compounds. We use proprietary software to ensure that each small molecule compound within a mixture can be uniquely identified by its mass. This obviates the need for artificial tagging methods, which adds preparation time and cost, and may interfere with the screening process.

Under this drug discovery collaboration, Licensor agreed to screen a number of proteins supplied to us by Licensee. Licensor maintains the option to develop some or all of the small molecule compounds Licensor identify.

IPSCIO Record ID: 249719

License Grant
Licensor grants the Japanese Licensee an exclusive, worldwide, right and license, within the Territory, to use the Licensor Know-How and Patent Rights and Licensors undivided interest in any Program Intellectual Property and Joint Program Patent Rights, as embodied in or related to any Designated Compounds, to research, develop, make, have made and use such Designated Compound to develop Licensed Products and to make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products.

This agreement includes non-exclusive terms as well.

License Property
The licensed property includes:
(a) the Ne0Morph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Candidate Compound A,
(e) the Candidate Compound B,
(d) the Candidate Compound C, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof and
(e) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Program, which is Controlled by Licensor, primarily relates to a Designated Compound or Licensed Products, whether or not patentable.

NeoMorph Chemistry means the process, proprietary to Licensor, of forming libraries and sub-libraries of discrete compounds by coupling a broad set of diverse cores with diverse sets of building blocks employing proprietary mass-coding algorithms.

NeoMorph Focused Libraries means those compounds synthesized by Licensor derived from Active Compounds identified by Licensee in bioassays or functional assays NeoMorph Screening Library means the entire collection of libraries consisting of mass-encoded small molecule organic compounds owned by Licensor and developed with NeoMorph Chemistry, comprising at least 10,000,000 different compounds.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets. Licensor has certain technology and know-how, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Field of Use
The Licensees intended use is for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

The Field means treatment of any disease in humans.

IPSCIO Record ID: 249722

License Grant
Licensor grants a worldwide right and license, without the right to sub license, within the Territory, to use the Licensor Intellectual Property and Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Compounds, Derivative Compounds thereof, Products and Shared Products and, Independent Compounds, Derivative Compounds thereof and Independent Products.

This agreement also contains non-exclusive grants for research.

License Property
Licensor has certain technology and know-how, including screening processes and libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Derivative Compounds means any analogs, homologs or isomers of a Designated Screening Compound, a Designated Shared Compound and/or an Independent Compound, as applicable. Designated Compounds means Designated Screening Compounds and Designated Shared Compounds.

Licensor Intellectual Property means, individually and collectively,
(a) all Inventions that are conceived, discovered, developed, generated, created, made or reduced to practice or tangible medium of expression solely by employees or consultants of Licensor at any time prior to the Effective Date, or after the Effective Date if such Inventions are not based upon or related to the performance of the Program;
(b) any tangible materials provided by Licensor to Licensee for use in the conduct of the Program, together with, where applicable, any analogs, derivatives, fragments, progeny, sub-cellular constituents or expression products thereof; and
( c) the NeoMorph Screening Library, ALIS and QSCD.
The term Licensor Intellectual Property, however, does not include any techniques, methodologies, know-how, information and data which is, as of the Effective Date, or later becomes, generally available to the public, other than such techniques, methodologies, know-how, information and data included in Licensor Patent Rights.

NeoMorph Screening Library means the entire collection of libraries consisting of mass-encoded small molecule organic compounds owned by Licensor and developed with NeoMorph Chemistry, comprising approximately ten million (10,000,000) different compounds.

ALIS means the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

QSCD means Quantized Surface Complimentary Diversity, a model proprietary to Licensor, pursuant to which discrete chemical compliments to the surfaces of a Target are defined.

Field of Use
Field means all preventative, therapeutic and diagnostic uses in humans.

IPSCIO Record ID: 249721

License Grant
Licensor grants to the English Licensee:
– an exclusive, worldwide, right and license, within the Territory to Licensor Technology and interest in any Program Technology, as embodied in or related to any Preliminary Compound(s), Primary Active Compound(s), QSCD Preliminary Compound(s), QSCD Primary Active Compound(s) and Designated Compounds solely for the purpose of conducting Licensees activities under the Research Collaboration, to research, develop, make, have made, use and import Preliminary Compound(s), Primary Active Compound(s), QSCD Preliminary Compound(s), QSCD Primary Active Compound(s) and Designated Compounds to develop Licensed Product(s); and

– an exclusive, worldwide, right and license, within the Territory, to the Licensors Technology and interest in any Program Technology, as embodied in or related to any Designated Compounds, necessary to make, have made, develop, have developed, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Product(s).

Licensee may grant sub-licenses.

License Property
Licensed Products shall mean any product whose pharmaceutical composition contains any formulation or dosage of a Designated Compound or any Licensee Derivatives or improvements thereof as a pharmaceutically active ingredient and the development, manufacture, use, or sale of which, absent the rights assigned and licenses granted to Licensee under this Agreement, would infringe the Licensor Technology or which makes use of any Patents comprised in Program Technology with respect to which Licensor is an inventor.

NeoMorph Chemistry shall mean the process, proprietary to Licensor, of forming libraries and sub-libraries of discrete compounds by coupling a broad set of diverse cores with diverse sets of building blocks employing proprietary mass-coding algorithms.

NeoMorph Focuses Libraries shall mean those compounds synthesized by Licensor during the optimization of either the Preliminary Compounds identified from the NeoMorph Screening Library or further optimization of compounds identified in any rounds of optimization.

NeoMorph Screening Library shall mean the constantly expanding collection of libraries consisting of mass-encoded small molecule organic compounds owned by Licensor and developed with NeoMorph Chemistry, currently comprising about 10,000,000 unique compounds.

Preliminary Compound shall mean any Licensor compound identified from the NeoMorph Screening Library which binds an Approved Target with a minimum affinity set by the Steering Committee on an Approved Target by Approved Target basis.

QSCD shall mean Quantisized Surface Complementary Diversity, a technology proprietary to Licensor, in terms of which discrete chemical complements to the surfaces of Approved Targets may be defined.

Field of Use
Licensee is a biopharmaceutical company with an ongoing interest in research, development and commercialization of pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high affinity and functional activity to protein targets for the development, manufacture and commercialization of pharmaceutical products.

IPSCIO Record ID: 249766

License Grant
Licensor grants to the French Licensee, an exclusive, worldwide, right and license, within the Territory, to use the Licensor Intellectual Property and Patent Rights with application to the Field to the extent necessary or useful to research, develop, make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Lead Compounds and Products.
License Property
NeoMorph Chemistry means the process, proprietaty to Licensor, of forming libraries and sub-libraries of discrete compounds by coupling a broad set of diverse cores with diverse sets of building blocks employing proprietary mass-coding algorithms.

Licensor Intellectual Property means, individually and collectively, all Inventions that are conceived, discovered, developed, generated, created, made or reduced to practice or tangible medium of expression solely by employees or consultants of Licensor at any time prior to the Effective Date or after the Effective Date; any tangible materials provided by Licensor to Licensee for use in the conduct of the Program, together with, where applicable, any analogs, derivatives, fragments, progeny, sub-cellular constituents or expression products thereof; and the NeoMorph Screening Library, the NeoMorph Focused Libraries, ALIS and QSCD. The Licensor Intellectual Property, however, does not include any know-how, processes, information and data which is, as of the Effective Date or later becomes, generally available to the public.

Derivative Compounds means any analog, homolog or isomer of a Lead Compound, which has an IC50 value against the Screening Target of twenty (20)  micromolar or less, which results from a chemical synthesis program based on the Lead Compounds or is based on structure-activity data of the Lead Compound; provided, that any such program or data is in respect of a target protein from other bacterial or fungal organisms homologous in origin and biological function to the original Screening Target.

Field of Use
The field means preventative, therapeutic and diagnostic uses in humans or animals.

IPSCIO Record ID: 249765

License Grant
For the License to Licensed Products,  Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to make, have made, use, distribute, promote, market, offer for sale, sell, import and export Licensed Products.

For License to Compounds, Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to research, develop, make, have made, import, export and use the Selected Compounds, and Active Compounds, Improved Active Compounds and Preliminary Compounds of the same Chemotype as such Selected Compounds, Designated Compounds and Derivative Compounds, for research purposes and to develop Licensed Products.

This agreement also includes non-exclusive grants for research.

License Property
Licensor has certain technology and knowhow, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Preliminary Compound means any Compound identified as having binding activity when tested against a Target pursuant to the Screening Program and which has Kd values of 10 micromolar or less (i.e., Kd ~ 1 OµM) or such other binding affinity threshold for a specific Target as shall be agreed upon by the parties in writing.

ALIS means the Automated Ligand Identification System, an automated, ultrahigh throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

OSCD means Quantisized Surface Complimentary Diversity, a model proprietary to Licensor, in terms of which discrete chemical compliments to the surfaces of a Target are defined.

Licensor Know-How means all proprietary information, data and know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries, NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, approved Active Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or Licensed Products together with, where applicable, any analogs, derivatives or fragments thereof.

Chemotype means a family or group of Compounds closely structurally related to one or more Active Compounds.

Field of Use
The Field means the treatment or prevention of any disease or condition in humans or animals.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

IPSCIO Record ID: 253904

License Grant
Licensor grants to English Licensee an exclusive, worldwide, right and license, within the Territory and within the Field, to use the Licensor Know-How and Patent Rights and Licensors undivided interest in any Program Intellectual Property that is jointly owned by the Parties, as embodied in or related to any Designated Compound(s), collectively, the Licensed Technology, to research, develop, make, have made and use such Designated Compound to develop Licensed Products, and, to make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products.
License Property
The parties pursue a collaborative screening process to identify compounds exhibiting a high degree of chemical binding activity to targets designated by Licensee from among the Licensor libraries of mass-encoded small molecule compounds and which have activity in bioassays or functional assays.

The know-how and patents include screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Licensed Product(s) means any product which includes a Designated Compound or any derivatives, improvements and components thereof; and the development, manufacture, use, or sale.

Licensor Library includes ALIS, the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to the Licensor that is used to identify multiple classes of chemical ligands against target protein.

Field of Use
The Field means the diagnosis or treatment of any disease in humans.  The Licensee is identifying potential pharmaceutical products for treatment of certain human diseases and is identifying compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

IPSCIO Record ID: 249720

License Grant
Licensor grants to Swiss Licensee, an exclusive right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to make, have made, use, distribute, promote, market, offer for sale, sell, import and export Licensed Products.

This agreement includes non-exclusive terms also.

License Property
Active Compound means any Compound identified as having binding activity when tested against a Target pursuant to the Screening Program and which has Kd values of 10 micromolar or less (i.e., Kd s 10µM) and has demonstrated bioactivity in functional assays against the applicable Target as determined by the Steering Committee.

Compound shall mean all proprietary compounds contained in the NeoMorph Screening Library or any NeoMorph Focused Libraries which are screened by Licensor against one or more Targets in performance of the Screening Program.

Field of Use
Field means the treatment or prevention of any disease or condition in humans or animals.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

Licensor will employ its Automated Ligand Identification System (ALIS) and its neoMorph compound library to help Licensee discover a range of antiviral candidates.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows:  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.

IPSCIO Record ID: 223155

License Grant
For the Research Program License for Licensor Technology, Licensor hereby grants to German Licensee a worldwide, non-exclusive, irrevocable license under the Licensor Technology during the term of the Research Program to conduct the Research Program.

For Other Licensor Patents, Licensor grants to Licensee irrevocable worldwide, exclusive license in the Field under such patent to make, have made, use, sell, have sold, import and have imported licensed Products, under the conditions stipulated in Article 6, provided that 3DP is not contractually prohibited from granting such an exclusive license.

For ThermoFluor Protein Characterization and Screening Technology, Licensor also grants to Licensee a nonexclusive license under the Licensor Technology to utilize the ThermoFluor Protein Characterization and Screening Technology within the Field also outside of the Research Program.

License Property
The Licensor Technology means patents for System, method, and computer program product for at least partially automatically generating chemical compounds with desired properties from a list of potential chemical compounds to synthesize, and, associated know-how and other intellectual property rights of Licensor that cover the use of DirectedDiversity Accessible Compound Libraries, DirectedDiversity Software Tools and ThermoFluor Protein Characterization and Screening Technology, and other related technology developed by Licensor during the course of this Agreement.

Licensed Product means any commercial product comprising of an Active Compound or a Research Program Compound or a compound synthesized by Licensee and covered by a Compound Patent, provided that the compound synthesized by Licensee results from Optimization Synthesis performed at Licensor on an Active Compound selected for optimization by Licensor.

The Probe library is the collection of discrete, structurally diverse small organic molecules synthesized at the Effective Date from the Accessible Compound Libraries, including additional compounds synthesized subsequently.

The Research Program Compound is a compound that has been synthesized by Licensor in the course of the Research Program, e.g., in the course of optimizing an Active Compound.

Field of Use
The Field means plant management, pest management, including fungi, and animal health, including but not limited to the use of herbicides, plant trait modifiers, plant growth regulators, pesticides, fungicides, animal health care, home and garden products, and environmental health products.  The term Field expressly excludes human diagnostic and human therapeutic products.

IPSCIO Record ID: 230755

License Grant
The parties entered into a research collaboration to allow Licensee and Licensor to identify Prototype Compounds active against selected targets that may be developed and commercialized by Licensee.
License Property
Target means a protein against which Hits are identified and Prototype Compounds are to be optimized in the Research Program. Targets, as defined herein, shall also include Replacement Targets once such targets become Targets.

Prototype Compound means a compound discovered using information obtained from a Hit in the course of Prototype Compound Generation having a dissociation constant less than or equal to 0.5 µM as determined in a dose response experiment and which demonstrates a desired activity against a Target in a molecular or cellular functional assay. Prototype Compounds will have pharmaceutically acceptable properties as determined by the Licensee prior to initiation of Prototype Compound Generation and confirmed in a series of in vitro assays, including p450 metabolism, p450 inhibition, logP, logD, pKa, Caco-2 permeability and solubility. Prototype Compounds will be identified as Prototype Compounds by the Licensee within thirty (30) days of delivery of data from such in vitro assays. For purposes of clarity, the Licensee may, at its discretion, select a compound as a Prototype Compound even if such compound does not meet the criteria set forth above.

Prototype Compound Generation means a program for discovering Prototype Compounds using information obtained from Hits, and iterative rounds of chemistry and the Licensor Synthetically Accessible Library to make Focused Libraries for rescreening using ThermoFluor(R) Technology against such Target.

Licensor Synthetically Accessible Library means Licensors virtual compound library as it exists from time to time from which Licensor Probe Libraries have been selected, and from which Focused Libraries will be selected.

Licensor Probe Library means the sample compound library or any subset thereof, comprised of proprietary and non-proprietary compounds which are owned or Controlled by Licensor or to the extent not encumbered by a bona fide third party interest, that have been synthesized for the purposes of fulfilling Licensors obligations under this Agreement, which is used for the screening of Targets using ThermoFluor(R) Technology for the purpose of identification of Hits, Prototype Compounds, or Active Compounds. While the individual non-proprietary compounds in the Licensor Probe Library are not proprietary, the collection itself, and the list, as a whole, of non-proprietary compounds included in the collection, are the 'Confidential Information' of Licensor.

Active Compound means a compound(s) claimed by a Valid Claim of a Licensor Patent, Joint Patent or Research Program Patent Right.

ThermoFluor(R) Technology means the technology described in:
(a)   the Licensor Patents identified below, and (b) associated proprietary Licensor Know-how used to evaluate ligand binding parameters of Hits, Prototype Compounds, and Active Compounds.

6,020,141 – Microplate Thermal Shift Assay for Ligand Development and Multi-variable Protein Chemistry Optimization
6,036,920 – Microplate Thermal Shift Assay for Ligand Development and Multi-variable Protein Chemistry Optimization
6,291,191 – Microplate Thermal Shift Assay for Ligand Development and Multi-variable Protein Chemistry Optimization

DirectedDiversity(R)Technology means the technology described in:
(a) the Licensor Patents identified below, and (b) associated proprietary Licensor know-how used to identify Hits, Prototype Compounds, and Active Compounds.

5,463,564 – System and Method of Automatically Generating Chemical Compounds with Desired Properties
5,574,656 – System and Method of Automatically Generating Chemical Compounds with Desired Properties
5,684,711 – System and Method of Automatically Generating Chemical Compounds with Desired Properties

Field of Use
Field means the research, development and commercialization of compounds for use in therapeutic, prophylactic and diagnostic products in humans or animals. The Field shall specifically exclude the field of treatment with, research on, and/or development of drugs whose principal aim is to treat or cure of infectious disease in humans; provided however, after March 7, 2003, the Field shall not have any such exclusion.

IPSCIO Record ID: 222557

License Grant
Licensor agrees to grant, and hereby grants to Licensee an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology (exclusive even as to Licensor and its Affiliates), to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory.  It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

Licensor agrees to grant, and hereby grants, to Licensee an exclusive license (exclusive even as to Licensor and its Affiliates), under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

License Property
The proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.

Combination Product shall mean a Product which comprises two (2) or more active therapeutic ingredients at least one (1) of which is an Agreement Compound or a Licensee Compound.

Library Compound shall mean any compound which is contained in a Discovery Library or Optimization Library hereunder.

Target shall mean a biomolecular entity (including, without limitation, receptors, enzymes, nucleic acids and proteins, and/or fragments thereof) that a small molecule is screened against in order to determine whether the small molecule demonstrates a specific biochemical or pharmaceutical effect.

Library shall mean any chemical compound library prepared by Licensor employees working on the Collaboration, and/or Licensee employees working at Licensors facilities on the Collaboration,  under the terms of this Agreement using (i) combinatorial chemistry techniques or (ii) such other techniques as may, from time to time, be agreed by the Parties.

Field of Use
This agreement pertains to the drug industry relating to therapeutic, treatment or prevention of diseases and conditions in human beings.

Licensor's combinatorial chemistry technology will accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.

IPSCIO Record ID: 279299

License Grant
This agreement is to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

For the License of proprietary rights,  Licensor grants a co-exclusive, with Licensor, worldwide right and license, without the right to sublicense, within the Territory, to use the Licensor Intellectual Property and Licensor Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Shared Compounds, Derivative Compounds thereof, Shared Products and, to the extent permitted Independent Compounds, Derivative Compounds thereof and Independent Products.

The research license portion is non-exclusive.

License Property
ALIS means the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

Licensor will screen at least five million (5,000,000) compounds contained in the Licensor NeoMorph Screening Library against each Shared Target.

Licensee will provide at least two hundred fifty (250) nmol. of each of the purified functionally-active Shared Target proteins.

Derivative Compounds means any analogs, homologs or isomers of a Designated Shared Compound and/or an Independent Compound, as applicable.

Field of Use
Field means all preventative, therapeutic and diagnostic uses of Shared Products or Independent Products with respect to human immunodeficiency virus (HIV) in humans.

Licensee is interested in identifying potential pharmaceutical products for the treatment of human immunodeficiency virus (HIV) and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

IPSCIO Record ID: 223145

License Grant
Licensor grants to Licensee such rights that it has to grant a worldwide, exclusive license, with right to sublicense, to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products, under any Patent Rights owned by Licensor that would otherwise be infringed by Licensee but for this license, including Research Program Patent Rights, and under the Know-how developed by Licensee relating to the Licensed Products, including the Research Program Know-how.

This DiscoverWorksâ„¢ agreement is a research and development collaboration to identify Initial Hits, Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds active against selected targets, and suitable, if required, for medicinal chemistry optimization, that may be developed and commercialized.

License Property
The patents include System and method of automatically generating chemical compounds with desired properties, and, Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization.

Licensed Product means any commercial product containing an Active Compound as an active ingredient.

Active Compound means a Program Lead Compound or a Pre-Clinical Lead Compound identified in the course of the Research Program, or compound further optimized from such a Program Lead Compound or a Pre-Clinical Lead Compound.

Chemical Optimization means the design, synthesis and identification of Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds using DiscoverWorksâ„¢ Technology and other technologies.

DiscoverWorks™ Technology means DirectedDiversity® Technology and ThermoFluor® Technology.

DirectedDiversity(R) Technology means the descriptions, figures and claims of the Patent Rights and associated proprietary Licensor Know-how used to identify potential therapeutic compounds.

ThermoFluor® Technology means the Patent Rights and associated proprietary Licensor Know-how used to evaluate ligand-binding parameters.

Field of Use
The Field means the research, development and commercialization of chemical compounds for use in therapeutic and diagnostic products, except for use in the treatment or cure of Hepatitis C Virus through March 7, 2003 in humans.

IPSCIO Record ID: 281539

License Grant
This agreement is to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

Licensor grants a co-exclusive with Licensor, worldwide right and license, without the right to sublicense, within the Territory, to use the Licensor Intellectual Property and Licensor Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Shared Compounds, Derivative Compounds thereof and Shared Products and, to the extent permitted Independent Compounds, Derivative Compounds thereof and Independent Products.

The research license portion is non-exclusive.

License Property
ALIS means the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to Licensee that is used to identify multiple classes of chemical ligands against a target protein.

Licensee will screen at least five million (5,000,000) compounds contained in the Licensee NeoMorph Screening Library against each Shared Target.

Licensor will provide Licensee with at least two hundred fifty (250) nmol. of each of the purified functionally-active Shared Target proteins.

Derivative Compounds means any analogs, homologs or isomers of a Designated Shared Compound and/or an Independent Compound, as applicable.

Field of Use
Field means all preventative, therapeutic and diagnostic uses of Shared Products or Independent Products with respect to human immunodeficiency virus (HIV) in humans.

IPSCIO Record ID: 211864

License Grant
For the Non-Exclusive Research License to Licensor Base Technology, Licensor grants a non-exclusive, world-wide license under the Base Technology to conduct research and development activities pursuant to the Research Plan, with no right to sublicense.   Licensor also grants the right to sublicense or transfer the rights granted under the Collaboration Technology to: Affiliates; and to Third Parties.
License Property
License agreement is for the development of orally bioavailable small-molecule compounds identified through the application of PTC’s proprietary GEMS (Gene Expression Modulation by Small Molecules) technology.

GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.

GEMS-UTR (Gene Expression Modulation by Small-Molecules Untranslated Region) is a proprietary screening technology for the identification of small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through the UTRs of mRNA molecules.

The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient.  The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.

Field of Use
Field shall mean the prevention, treatment or diagnosis of all diseases or conditions in humans or animals.

This agreement pertains to drug discovery.

IPSCIO Record ID: 279318

License Grant
For the exclusive license, Licensor grants to the Licensee of Japan an exclusive right and license in the Territory under Licensors interest in the Collaboration Patent and the Collaboration Know-How, with a right to sublicense, to develop, make, have made, use, offer for sale and/or sell, import and export any Active Compound, Active Claimed Compound and/or Derivative Compound, and, also with a right to sublicense, to develop, make, have made, use, import and export, offer for sale and/or sell any Collaboration Product or Product.

For the Non-Exclusive Licenses for:
—  The Collaboration Technology, Licensor grants to a non-exclusive, sublicensable license in the Territory under Licensors interest in the Collaboration Patent and the Collaboration Know-How, to develop, make, have made, use, offer to sell, sell, import and export any Inactive Compound or Claimed Compound, other than Active Claimed Compounds, and upon Licensees discovery that a particular Inactive Compound or such Claimed Compound is active against a particular target, the right to negotiate to obtain the exclusive rights to such Inactive Compound or Claimed Compound, in each case in the Territory.
—  The Pre-existing Licensor Patents, In the event that the development, making, having made, use, offer for sale, sale, import and export by Licensee of any Active Compound, Inactive Compound, Active Claimed Compound, Claimed Compound or Derivative Compound, any Collaboration Product, Product or any product containing an Inactive Compound, a Claimed Compound or Derivative Compound would infringe during the term of the Agreement a claim of Pre-existing Licensor Patent, Licensor grants to the extent Licensor is legally able to do so, a non-exclusive, sublicensable, license in the Territory under such Pre-existing Licensor Patent for those purposes, and,
— The Inactive Compounds and Claimed Compounds, with respect to an Inactive Compound or a Claimed Compound, at least 90 days prior to Licensor entering into material and substantial negotiations to grant to a Third Party any rights to such Inactive Compound or Claimed Compound, Licensor agrees to notify Licensee in writing, together with a description of the chemical entity that would be the subject of such negotiations. Within 30 days after receipt from Licensor of such notice, Licensee shall notify Licensor whether or not it desires to discuss terms and conditions under which Licensor would grant exclusive rights to such Inactive or Claimed Compound to Licensee.

License Property
Licensor has expertise and proprietary technology for the discovery, generation, optimization and preclinical testing of small molecule clinical candidates from drug discovery programs.
Field of Use
The Field means the discovery, development and commercialization of small molecules for the diagnosis or therapeutic or prophylactic treatment of diseases and conditions, wherein the primary mechanism of action of such small molecules is to modulate the activity of a Collaboration Target.

IPSCIO Record ID: 223154

License Grant
For Ownership of Licensor Accessible Libraries and Licensor Patents, Licensor grants a worldwide, exclusive license, including the right to sublicense, in the Field under such patent to make, have made, use, sell, have sold, import and have imported Licensed Products, provided that Licensor is not contractually prohibited from granting such an exclusive license.  

For the License Under All Licensor Research Program Patents, Licensor grants a non-exclusive license in the Field under all Research Program Patents owned by Licensor to the extent such patents cover making, using, selling, offering for sale or importing a Qualified Lead Compound, an Active Compound or a Licensed Product.

License Property
Licensor DirectedDiversity(R) Technology means Licensor Patents and know-how in effect at the time of the Effective Date of this Agreement that relate to generating and utilizing a DirectedDiversity(R) Chemical Library,  including patents for System, method, and computer program product for at least partially automatically generating chemical compounds with desired properties from a list of potential chemical compounds to synthesize. This term also includes any discoveries, improvements, inventions and modifications made during the Research Program to the extent that they relate to Licensor DirectedDiversity(R) Technology.

DirectedDiversity® Chemical Library means a computer-generated library of compounds containing integrated structure•activity and synthesis data.

Active Compound means a Qualified Lead Compound or a compound derived from a Qualified Lead Compound that has been formally selected by Licensee after recommendation by the Research Steering Committee for preclinical development as evidenced by initiation of a Licensee supported range finding toxicology study to be performed by the Licensee Toxicology Department or its designate.

The Licensed Product means any commercial product containing an Active Compound.  

Licensor Accessible Libraries means anyDirectedDiversity® Chemical Library that is generated by Licensor outside of the Research Program.

Field of Use
The Field is human therapeutic and diagnostic uses of Qualified Lead Compounds or Active Compounds against Targets.

IPSCIO Record ID: 211827

License Grant
The parties wish to collaborate in a chemical lead and drug discovery program.  This agreement has an exclusive period.  Licensee has a non-exclusive right to use Licensors Technology as necessary to conduct activities under the Research Program.  Additionally, Licensor grants an exclusive, worldwide license, with the right to sublicense to use such Licensor Technology as is necessary to make, have made, use, have used, sell, have sold, import and export Active Compounds, Development Compounds and/or Products in the Territory.
License Property
Licensor has developed, licensed and/or owns certain drug discovery technology and intellectual property rights, including chemical library design software, multi-parallel synthesis and purification methods, chemical libraries suitable for high throughput biological screening assays and medicinal chemistry (collectively, 'CombiChem Technology').

Licensee desires to utilize CombiChem Technology for its drug discovery activities under Licensee know-how concerning the identification and characterization of novel small molecule inhibitors for development as therapeutics for treatment of diseases in humans.

Licensee and its Affiliates have developed and own certain drug discovery and intellectual property rights, including certain assays, methods and know how regarding the Initial Target, among other things (collectively 'ICOS Technology').

The Product means any product containing an Active Compound or Development Compound with such compound as the active ingredient or one of the active ingredients, which is the subject of one or more claims under a Collaboration Patent and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field.

The Product means any product containing an Active Compound or Development Compound with such compound as the active ingredient or one of the active ingredients, which is the subject of one or more claims under a Collaboration Patent and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field.

Field of Use
The Field means all therapeutic indications in humans for any Target against which a Collaboration Compound, Active Compound, Development Compound or Products may be directed.

IPSCIO Record ID: 223131

License Grant
Licensee hereby grants to Licensor a worldwide, non-exclusive license under the Research Program Technology and Licensor Inhibition Mode Technology solely to perform its obligations under the Research Program as specifically provided in the Research Plan.

Licensor hereby grants to Licensee and its Affiliates a worldwide, non-exclusive license under the Licensor Core Technology (and any improvements thereto) to research, develop, make, have made, use, import, offer for sale, sell, have sold or otherwise exploit compounds that inhibit the Target (including but not limited to Program Compounds) and/or Products in the Territory.

Licensor hereby grants to Licensee and its Affiliates a worldwide, non-exclusive license under the Licensor Background Technology to research, develop, make, have made, use, import, offer for sale, sell, have sold or otherwise exploit compounds that inhibit the Target (including but not limited to Program Compounds) and/or Products in the Territory.

License Property
Research Program means the activities undertaken by or under authority of Licensee, which may include input from Licensor and the Licensor Principal Consultant, to discover and develop Program Compounds as set forth and in the Research Plan.

Research Program Technology means Research Program Know-How and Research Program Patents.
Research Program Patents mean Licensee Research Program Patents, Licensor Research Program Patents, and Joint Research Program Patents.

Licensor Inhibition Mode Technology means Licensor Inhibition Mode Patents and Licensor Inhibition Mode Know-How.

Patents within the Licensor Core Technology.
U.S. Patent No. 6,344,330 – Pharmacophore Recombination For the Identification of Small Molecule Drug Lead Compounds
U.S. Patent No. 6,335,155 – Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules

Licensor Core Technology mean all patents, patent applications, invention disclosures, certificates of invention and applications for certificates of invention, owned or Controlled by Licensor or its Affiliates as of the Agreement’s Effective Date and/or during the term of the Agreement, and all information, materials and other subject matter, and improvements thereof, relating to (i) mutants or the use thereof in screening, (ii) the use of novel protein engineering techniques and their application in drug discovery, (iii) target-directed fragment discovery and maturation to produce drug leads, including monophores, extenders and fragments, and monophore, extender and fragment libraries for such purposes, (iv) covalent tethering and techniques related thereto (e.g., NMR, X-ray, mass spec. AUC, Biacore) and its use to discover fragments and test binding hypotheses of fragments and leads, or (v) dynamic and other combinatorial chemistries related to proteins, as well as any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions, supplementary protection certificates, and other governmental actions which extend any of the patent applications, patents, invention disclosures, certificates of invention or certificates of invention applications above, and all foreign counterparts to any of the foregoing.  Notwithstanding the foregoing, Licensor Core Technology shall exclude all Licensor Inhibition Mode Technology and Research Program Technology.

Licensor Background Technology means all patents, patent applications, invention disclosures, certificates of invention and applications for certificates of invention, Controlled by Licensor or its Affiliates as of the Effective Date and/or during the term of the Agreement, that (i) are necessary or useful to Licensee in the research, development, or commercialization of compounds that inhibit the Target (including but not limited to Program Compounds and Products), and (ii) are not Licensor Inhibition Mode Patents, Research Program Patents or within the Licensor Core Technology; as well as any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions, supplementary protection certificates, and other governmental actions which extend any of the patent applications, patents, invention disclosures, certificates of invention or certificates of invention applications above, and all foreign counterparts to any of the foregoing.

Field of Use
Research collaboration agreement relates to discover novel oral drugs for the treatment of viral infections.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.